# LZM009 to Treat Patients With Advanced Solid Tumors

> **NCT03286296** · PHASE1 · COMPLETED · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 30 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection

## Key facts

- **NCT ID:** NCT03286296
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-21
- **Primary completion:** 2019-03-06
- **Final completion:** 2019-04-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03286296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03286296, "LZM009 to Treat Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03286296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*